(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 8.3MM | +26% |
Operating Income | -36.3MM | - |
Operating Expenses | 44.6MM | - |
Net Income | -177.7MM | - |
R&D | 22.4MM | +73% |
G&A | 22.2MM | - |
Interest Expense | 0 | -100% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – –
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it has entered into an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its development and commercialization partner, Swedish Orphan Biovitrum AB (publ.) (
A Watertown biotech trimmed its pipeline again, setting aside all of its experimental drugs except one. It's the second time the company has cut programs this year. Plus other life sciences news you may have missed.
Q2 2023 Selecta Biosciences Inc Earnings Call
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 22.22% and 46.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conf
Key Insights Selecta Biosciences' significant individual investors ownership suggests that the key decisions are...
In this piece, we will take a look at the ten best revenue growth stocks to buy. If you want to skip over the latest news for the stock market and want to jump ahead to the top five stocks in this list, then take a look at 5 Best Revenue Growth Stocks to Buy. […]
It's nice to see the Selecta Biosciences, Inc. ( NASDAQ:SELB ) share price up 22% in a week. But will that repair the...